Weight gain from novel antipsychotic drugs: Need for action

被引:113
作者
Green, AI
Patel, JK
Goisman, RM
Allison, DB
Blackburn, G
机构
[1] Commonwealth Res Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Massachusetts Mental Hlth Ctr, Dept Psychiat, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Dept Surg, Beth Israel Deaconess Med Ctr,Div Nutr, Boston, MA 02115 USA
[4] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Obes Res Ctr, New York, NY 10032 USA
关键词
D O I
10.1016/S0163-8343(00)00081-5
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Obesity is common in schizophrenia, and people with schizophrenia appear to be at increased risk for certain obesity-related conditions, such as type 2 diabetes and cardiovascular disease. Antipsychotic drugs, used chronically to control symptoms of schizophrenia, are associated with often-substantial weight gain, a side effect that is a special concern with the latest generation of highly effective "novel" agents. That the mo,st effective (e.g., novel) antipsychoric medications lead to substantial weight gain presents the field with a critical public health problem. Although preliminary data have been reported regarding the beneficial use of behavior therapy programs for short-term weight control in patients with schizophrenia, the available data are quite limited, anti there are no data regarding the long-term beneficial effects of these programs in this population. The obesity field recently has developed programs emphasizing "lifestyle changes" (e.g., diet, exercise, and problem-solving skills) to successfully manage weight in patients without schizophrenia. Such programs can be adapted for patients with schizophrenia through the use of highly structured and operationalized modules emphasizing medication compliance, social skills development, and participation DI outpatient programs. Moreover, these programs can potentially be combined with the use of adjunctive pharmacotherapy to maximize and maintain weight loss. The field must solve the paradox that some of our most effective medications for schizophrenia produce substantial weight gain and its associated troubling health risks. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:224 / 235
页数:12
相关论文
共 164 条
[31]   Cognitive deficit in schizophrenia and its neurochemical basis [J].
Breier, A .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :16-18
[32]   Serum leptin levels increase rapidly after initiation of clozapine therapy [J].
Bromel, T ;
Blum, WF ;
Ziegler, A ;
Schulz, E ;
Bender, M ;
Fleischhaker, C ;
Remschmidt, H ;
Krieg, JC ;
Hebebrand, J .
MOLECULAR PSYCHIATRY, 1998, 3 (01) :76-80
[33]   Excess mortality of schizophrenia - A meta-analysis [J].
Brown, S .
BRITISH JOURNAL OF PSYCHIATRY, 1997, 171 :502-508
[34]  
Bustillo JR, 1996, AM J PSYCHIAT, V153, P817
[35]   Olanzapine: a basic science update [J].
Bymaster, F ;
Perry, KW ;
Nelson, DL ;
Wong, DT ;
Rasmussen, K ;
Moore, NA ;
Calligaro, DO .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :36-40
[37]  
Casey DE, 1996, J CLIN PSYCHIAT, V57, P40
[38]  
CENTORRINO F, 1994, J CLIN PSYCHOPHARM, V14, P119
[39]   OBESITY, FAT DISTRIBUTION, AND WEIGHT-GAIN AS RISK-FACTORS FOR CLINICAL DIABETES IN MEN [J].
CHAN, JM ;
RIMM, EB ;
COLDITZ, GA ;
STAMPFER, MJ ;
WILLETT, WC .
DIABETES CARE, 1994, 17 (09) :961-969
[40]   Phentermine, psychosis, and family history [J].
Cleare, AJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (06) :470-471